Medgend Icon

Ledgend of Medicine







discontinued


Xarelto FDA Approved Drugs

XARELTO [RivaroxabanC19H18ClN3O5S]
RX
-
10mg (oral tablet)
15mg (oral tablet)
20mg (oral tablet)
Janssen PharmsJul 1, 2011
  • Following initial 6 months treatment for deep vein thrombosis (dvt) and/or pulmonary embolism (pe), reduction in the risk of recurrence of dvt and of pe with once daily, rapid-release tablet administered for at least five consecutive days.
  • Prophylaxis of deep vein thrombosis (dvt).
  • Prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism in patients undergoing knee or hip replacement surgery, with once daily, rapid-release tablet administered for at least five consecutive days.
  • Reduce the risk of stroke in patients with nonvalvular atrial fibrillation with once daily, rapid-release tablet administered for at least five consecutive days.
  • Reducing the risk of stroke and systemic embolism.
  • Reduction in the risk of recurrence of deep vein thrombosis (dvt) and pulmonary embolism.
  • Treatment of deep vein thrombosis (dvt).
  • Treatment of deep vein thrombosis with once daily, rapid-release tablet administered for at least five consecutive days.
  • Treatment of pulmonary embolism (pe).
  • Treatment of pulmonary embolism with once daily, rapid-release tablet administered for at least five consecutive days.
efficacy
4.0  (1)
side effects
0.0  (0)
danger
0.0  (0)

UNK

WARNING: Consult a licensed physician in the appropriate field for medical treatment and drug prescription. Do not self medicate.